At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-centre, Open-label, Randomised Explorative Pharmacokinetic/Pharmacodynamic Study of the Gonadotropin-releasing Hormone Receptor Antagonist Degarelix (FE 200486) in Patients With Benign Prostatic Hyperplasia.
In Brief
A Phase 2 clinical trial evaluating Degarelix for BPH. Completed, enrolled 52 participants across 1 site.
Detailed Summary
This exploratory study will be conducted open label in a single investigational clinical unit. Altogether 52 patients with benign prostate hyperplasia (BPH) will be randomly assigned to receive 4 different treatments with degarelix.
Study Details
Timeline
Interventions
Two doses of 16 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
One dose of 32 mg administered as a single administration will be evaluated for 42 days.
Two doses of 32 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
One dose of 64 mg administered as a single administration will be evaluated for 42 days.